Sensyne Health plc announced that it has signed a five-year, non-exclusive Strategic Research Agreement ("SRA") with Cambridge University Hospitals NHS Foundation Trust ("CUH" or the "Trust"). The agreement will enable the ethical application of clinical AI research by analysing de-identified patient records in order to carry out research with the potential of providing new understanding and treatments for various diseases. The partnership will cover research across the Trust's areas of disease expertise and specialism in cancer, cardiovascular disease, and rare diseases. These are vital areas of research which CUH wants to support to provide equitable access to diagnosis and treatment for its patient population, while also helping address future national and international health challenges. Cancer research will be a key focus of the strategic research partnership and Sensyne will use its expertise to analyse cancer patient pathways to reduce patient waiting times and improve patient care. Additionally, under the SRA, Sensyne and CUH will focus on the following areas: Clinical decision tools to support patient care, by developing and validating the effectiveness of new AI-enabled software tools to help clinicians analyse complex data sets to improve clinical decision making; The use of AI for the analysis of retrospective clinical data, and the generation of synthetic control arms to support clinical trials more effectively, accelerating the process of drug development for patients; and Drug discovery, by helping to discover new medicines aimed at treating rare as well as common diseases, including cardiovascular disease and cancers.